Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
  • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

• the present invention is directed to the novel use of a peptide class of compound for treating different types and symptoms of acute and chronic pain, especially non neurophathic inflammatory pain.
• Certain peptides are known to exhibit central nervous system (CNS) activity and are useful in the treatment of epilepsy and other CNS disorders. These peptides which are described in the U.S. Patent No. 5,378,729 have the Formula (I):
• R is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, aryl lower alkyl, heterocyclic, heterocyclic lower alkyl, lower alkyl heterocyclic, lower cycloalkyl, lower cycloalkyl lower alkyl, and R is unsubstituted or is substituted with at least one electron withdrawing group or electron donating group;
• Ri is hydrogen or lower alkyl, lower alkenyl, lower alkynyl, aryl lower alkyl, aryl, heterocyclic lower alkyl, heterocyclic, lower cycloalkyl, lower cycloalkyl lower alkyl, each unsubstituted or substituted with an electron donating group or an electron withdrawing group;
• R 2 and R 3 are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl lower alkyl, aryl, heterocyclic, heterocyclic lower alkyl, lower alkyl heterocyclic, lower cycloalkyl, lower cycloalkyl lower alkyl, or Z-Y wherein R 2 and R 3 may be unsubstituted or substituted with at least one electron withdrawing group or electron donating group;
• Z is O, S, S(O) 2 , NR 4 , PR or a chemical bond
• Y is hydrogen, lower alkyl, aryl, aryl lower alkyl, lower alkenyl, lower alkynyl, halo, heterocyclic, heterocyclic lower alkyl, and Y may be unsubstituted or substituted with an electron donating group or an electron withdrawing group, provided that when Y is halo, Z is a chemical bond, or
• ZY taken together is NR4NR5R7, NR OR 5 , ONR 4 R 7> OPR4R5, PR4OR5, SNR 4 R 7 , NR4SR7, SPR 4 R 5 or PR4SR7, NR 4 PR 5 R 6 or PR 4 NR 5 R7,
• R 4 , R 5 and R 6 are independently hydrogen, lower alkyl, aryl, aryl lower alkyl, lower alkenyl, or lower alkynyl, wherein R 4 , R 5 and R 6 may be unsubstituted or substituted with an electron withdrawing group or an electron donating group; and
• R 7 is R 6 or COOR 8 or COR 8 ;
• R8 is hydrogen or lower alkyl, or aryl lower alkyl, and the aryl or alkyl group may be unsubstituted or substituted with an electron withdrawing group or an electron donating group; and n is 1-4; and a is 1-3.
• U.S. Patent No. 5,773,475 also discloses additional compounds useful for treating CNS disorders. These compounds are N-benzyl-2-amino-3-methoxy-propionamide having the Formula (II):
• Ar is aryl which is unsubstituted or substituted with halo; R 3 is lower alkoxy; and Ri is lower alkyl especially methyl.
• the present invention relates to the novel use of a compound having
• Formula (I) and/or Formula (II) showing antinociceptive properties for treating different types and symptoms of acute and chronic pain, especially non neuropathic inflammatory pain.
• the present invention concerns the use of said compounds of Formulae (I) and/or (II) for the preparation of a pharmaceutical composition for the treatment of different types and symptoms of acute and chronic pain, especially non neuropathic inflammatory pain.
• This include chronic inflammatory pain e.g. rheumatoid arthritis pain and/or secondary inflammatory osteoarthritic pain.
• a compound according to the invention has the general Formula (I)
• R is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, aryl lower alkyl, heterocyclic, heterocyclic lower alkyl, lower alkyl heterocyclic, lower cycloalkyl, lower cycloalkyl lower alkyl, and R is unsubstituted or is substituted with at least one electron withdrawing group, or electron donating group;
• Ri is hydrogen or lower alkyl, lower alkenyl, lower alkynyl, aryl lower alkyl, aryl, heterocyclic lower alkyl, heterocyclic, lower cycloalkyl, lower cycloalkyl lower alkyl, each unsubstituted or substituted with an electron donating group or an electron withdrawing group;
• R 2 and R 3 are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl lower alkyl, aryl, heterocyclic, heterocyclic lower alkyl, lower alkyl heterocyclic, lower cycloalkyl, lower cycloalkyl lower alkyl, or Z-Y wherein R 2 and R may be unsubstituted or substituted with at least one electron withdrawing group or electron donating group; Z is O, S, S(O) 2 , NR 4 , PR 4 or a chemical bond;
• Y is hydrogen, lower alkyl, aryl, aryl lower alkyl, lower alkenyl, lower alkynyl, halo, heterocyclic, heterocyclic lower alkyl, lower alkyl, and Y may be unsubstituted or substituted with an electron donating group or an electron withdrawing group, provided that when Y is halo, Z is a chemical bond, or
• ZY taken together is NR 4 NR 5 R 7 , NR4OR5, ONR4R7, OPR4R5, PR4OR5, SNR 4 R 7 , NR 4 SR 7 , SPR4R5 or PR 4 SR 7l NR4PR5R6 or PR 4 NR 5 R 7 ,
• R , R 5 and Re are independently hydrogen, lower alkyl, aryl, aryl lower alkyl, lower alkenyl, or lower alkynyl, wherein R4, R 5 and R 6 may be unsubstituted or substituted with an electron withdrawing group or an electron donating group;
• R 7 is independently R 6 or COOR 8 or COR 8 ;
• R 8 is hydrogen or lower alkyl, or aryl lower alkyl, and the aryl or alkyl group may be unsubstituted or substituted with an electron withdrawing group or an electron donating group;
• Ar is aryl which is unsubstituted or substituted with halo; R 3 is lower alkoxy; and Ri is lower alkyl, especially methyl.
• the present invention is also directed to the preparation of pharmaceutical compositions comprising a compound according to Formula (I) and/or Formula (II) useful for the treatment of rheumatic inflammatory pain.
• the compounds of Formula I are useful for treating pain, particularly non neuropathic inflammatory pain.
• This type of pain includes chronic inflammatory pain e.g. rheumatoid arthritis pain and/or secondary inflammatory osteoarthritic pain. They show an anti-nociceptive effectiveness.
• alkyl groups when used alone or in combination with other groups, are lower alkyl containing from 1 to 6 carbon atoms and may be straight chain or branched. These groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, amyl, hexyl, and the like.
• aryl lower alkyl groups include, for example, benzyl, phenethyl, phenpropyl, . phenisopropyl, phenbutyl, diphenylmethyl, 1,1-diphenylethyl, 1 ,2-diphenylethyl, and the like.
• aryl when used alone or in combination, refers to an aromatic group which contains from 6 up to 18 ring carbon atoms and up to a total of 25 carbon atoms and includes the polynuclear aromatics. These aryl groups may be monocyclic, bicyclic, tricyclic or polycyclic and are fused rings.
• a polynuclear aromatic compound as used herein, is meant to encompass bicyclic and tricyclic fused aromatic ring systems containing from 10-18 ring carbon atoms and up to a total of 25 carbon atoms.
• the aryl' group includes phenyl, and the polynuclear aromatics e.g., naphthyl, anthracenyl, phenanthrenyl, azulenyl and the like.
• the aryl group also includes groups like ferrocyenyl.
• “Lower alkenyl” is an alkenyl group containing from 2 to 6 carbon atoms and at least one double bond.
• These groups may be straight chained or branched and may be in the Z or E form.
• Such groups include vinyl, propenyl, 1-butenyl, isobutenyl, 2-butenyl, 1-pentenyl, (Z)-2-pentenyl, (E)-2-pentenyl, (Z)-4-methyl-2-pentenyl, (E)-4-methyl-2-pentenyl, pentadienyl, e.g., 1 , 3 or 2,4-pentadienyl, and the like.
• alkynyl is an alkynyl group containing 2 to 6 carbon atoms and may be straight chained as well as branched. It includes such groups as ethynyl, propynyl, 1- butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-methyl-1-pentynyl, 3-pentynyl, 1-hexynyl, 2- hexynyl, 3-hexynyl and the like.
• cycloalkyl when used alone or in combination is a cycloalkyl group containing from 3 to 18 ring carbon atoms and up to a total of 25 carbon atoms.
• the cycloalkyl groups may be monocyclic, bicyclic, tricyclic, or polycyclic and the rings are fused.
• the cycloalkyl may be completely saturated or partially saturated.
• Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclohexenyl, cyclopentenyl, cyclooctenyl, cycloheptenyl, decalinyl, hydroindanyl, indanyl, fenchyl, pinenyl, adamantyl, and the like.
• Cycloalkyl includes the cis or trans forms.
• the substituents may either be in endo or exo positions in the bridged bicyclic systems.
• electron-withdrawing and electron donating refer to the ability of a substituent to withdraw or donate electrons, respectively, relative to that of hydrogen if the hydrogen atom occupied the same position in the molecule. These terms are well understood by one skilled in the art and are discussed in Advanced Organic Chemistry, by J. March, John Wiley and Sons, New York, NY, pp.16-18 (1985) and the discussion therein is incorporated herein by reference.
• Electron withdrawing groups include halo, including bromo, fluoro, chloro, iodo and the like; nitro, carboxy, lower alkenyl, lower alkynyl, formyl, carboxyamido, aryl, quaternary ammonium, trifluoromethyl, aryl lower alkyanoyl, carbalkoxy and the like.
• Electron donating groups include such groups as hydroxy, lower alkoxy, including methoxy, ethoxy and the like; lower alkyl, such as methyl, ethyl, and the like; amino, lower alkylamino, di(loweralkyl) amino, aryloxy such as phenoxy, mercapto, lower alkylthio, lower alkylmercapto, disulfide (lower alkyldithio) and the like.
• substituents may be considered to be electron donating or electron withdrawing under different chemical conditions.
• the present invention contemplates any combination of substituents selected from the above-identified groups.
• halo includes fluoro, chloro, bromo, iodo and the like.
• acyl includes lower alkanoyl.
• the heterocyclic substituent contains at least one sulfur, nitrogen or oxygen ring atom, but also may include one or several of said atoms in the ring.
• the heterocyclic substituents contemplated by the present invention include heteroaromatics and saturated and partially saturated heterocyclic compounds. These heterocyclics may be monocyclic, bicyclic, tricyclic or polycyclic and are fused rings. They may contain up to 18 ring atoms and up to a total of 17 ring carbon atoms and a total of up to 25 carbon atoms.
• the heterocyclics are also intended to include the so-called benzoheterocyclics.
• heterocyclicx include furyl, thienyl, pyrazolyl, pyrrolyl, imidazolyl, indolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, piperidyl, pyrrolinyl, piperazinyl, quinolyl, triazolyl, tetrazolyl, isoquinolyl, benzofuryl, benzothienyl, morpholinyl, benzoxazolyl, tetrahydrofuryl, pyranyl, indazolyl, purinyl, indolinyl, pyrazolindinyl, imidazolinyl, imadazolindinyl, pyrrolidinyl, furazanyl, N-methylindolyl, methylfuryl, pyridazinyl, pyrimidinyl, pyrazinyl, pyridyl, epoxy, aziridino
• the preferred heterocyclic are thienyl, furyl, pyrrolyl, benzofuryl, benzothienyl, indolyl, methylpyrrolyl, morpholinyl, pyridiyl, pyrazinyl, imidazolyl, pyrimidinyl, or pyridazinyl.
• the preferred heterocyclic is a 5 or 6-membered heterocyclic compound.
• the especially preferred heterocyclic is furyl, pyridyl, pyrazinyl, imidazolyl, pyrimidinyl, or pyridazinyl.
• the most preferred heterocyclics are furyl and pyridyl.
• R is aryl lower alkyl, especially benzyl especially those wherein the phenyl ring thereof is unsubstituted or substituted with electron donating groups or electron withdrawing groups, such as halo (e.g., F).
• the preferred Ri is H or lower alkyl.
• the most preferred Ri group is methyl.
• the most preferred electron donating substituents and electron withdrawing substituents are halo, nitro, alkanoyl, formyl, arylalkanoyl, aryloyl, carboxyl, carbalkoxy, carboxamido, cyano, sulfonyl, sulfoxide, heterocyclic, guanidine, quaternary ammonium, lower alkenyl, lower alkynyl, sulfonium salts, hydroxy, lower alkoxy, lower alkyl, amino, lower alkylamino, di(loweralkyl)amino, amino lower alkyl, mercapto, mercaptoalkyl, alkylthio, and alkyldithio.
• sulfide encompasses mercapto, mercapto alkyl and alkylthio, while the term disulfide encompasses alkyldithio. These preferred substituents may be substituted on any one of Ri, R 2 , R3. R4, R5 or R 6 , R 7 or R 8 as defined herein.
• the ZY groups representative of R2 and R 3 include hydroxy, alkoxy, such as methoxy, ethoxy, aryloxy, such as phenoxy; thioalkoxy, such as thiomethoxy, thioethoxy; thioaryloxy such as thiophenoxy; amino; alkylamino, such as methylamino, ethylamino; arylamino, such as anilino; lower dialkylamino, such as, dimethylamino; trialkyl ammonium salt, hydrazino; alkylhydrazino and arylhydrazino, such as N-methylhydrazino, N- phenylhydrazino, carbalkoxy hydrazino, aralkoxycarbonyl hydrazino, aryloxycarbonyl hydrazino, hydroxylamino, such as N-hydroxylamino (-NH-OH), lower alkoxy amino [(NHOR-is) wherein R-
• the preferred heterocyclic groups representative of R 2 and R 3 are monocyclic heterocyclic moieties the formula:
• n 0 or 1 ;
• R 50 is H or an electron withdrawing group or electron donating group
• A, Z, L and J are independently CH, or a heteroatom selected from the group consisting of N, O, S;
• G is CH, or a heteroatom selected from the group consisting of N, O and S,
• n O
• G CH
• a heteroatom selected from the group consisting of NH, O and S with the proviso that at most two of A, E, L, J and G are heteroatoms.
• heteroaromatic moiety When n is O, the above heteroaromatic moiety is a five membered ring, while if n is 1 , the heterocyclic moiety is a six membered monocyclic heterocyclic moiety.
• the preferred heterocyclic moieties are those aforementioned heterocyclics which are monocyclic.
• R 2 or R3 When R 2 or R3 is a heterocyclic of the above formula, it may be bonded to the main chain by a ring carbon atom. When n is O, R2 or R3 may additionally be bonded to the main chain by a nitrogen ring atom.
• R2 and R 3 are hydrogen, aryl, e.g., phenyl, aryl alkyl, e.g., benzyl and alkyl. It is to be understood that the preferred groups of R 2 and R 3 may be unsubstituted or substituted with electron donating or electron withdrawing groups.
• R 2 and R 3 are independently hydrogen, lower alkyl, which is either unsubstituted or substituted with an electron withdrawing group or an electron donating group, such as lower alkoxy (e.g., methoxy, ethoxy, and the like), N-hydroxylamino, N-lower alkylhydroxyamino, N-loweralkyl-O-loweralkyl and alkylhydroxyamino.
• one of R 2 and R 3 is hydrogen. It is preferred that n is one.
• R 2 is hydrogen and R3 is hydrogen, an alkyl group which is unsubstituted or substituted by at least an electron donating or electron withdrawing group or ZY.
• R 3 is hydrogen, an alkyl group such as methyl, which is unsubstituted or substituted by an electron donating group, or NR 4 OR 5 or ONR4R 7 , wherein R 4 , R 5 and R 7 are independently hydrogen or lower alkyl.
• the electron donating group is lower alkoxy, and especially methoxy or ethoxy.
• R is aryl lower alkyl.
• the most preferred aryl for R is phenyl.
• the most preferred R group is benzyl.
• the aryl group may be unsubstituted or substituted with an electron donating or electron withdrawing group. If the aryl ring in R is substituted, it is most preferred that it is substituted with an electron withdrawing group, especially on the aryl ring.
• the most preferred electron withdrawing group for R is halo, especially fluoro.
• the preferred Ri is loweralkyl, especially methyl.
• the more preferred compounds are compounds of Formula (I) wherein n is 1; R 2 is hydrogen; R 3 is hydrogen, an alkyl group, especially methyl which is substituted by an electron donating or electron withdrawing group or ZY; R is aryl, aryl lower alkyl, such as benzyl, wherein the aryl group is unsubstituted or substituted and R-i is lower alkyl.
• R 3 is hydrogen, an alkyl group, especially methyl, substituted by electron donating group, such as lower alkoxy, (e.g., methoxy, ethoxy and the like), NR4OR5 or ONR 4 R7 wherein these groups are defined hereinabove.
• the most preferred compounds utilized are those of the Formula (ll):
• Ar is aryl, especially phenyl, which is unsubstituted or substituted with at least one electron donating group or electron withdrawing group,
• Ri is lower alkyl
• R 3 is as defined herein, but especially hydrogen, loweralkyl, which is unsubstituted or substituted by at least an electron donating group or electron withdrawing group or ZY. It is even more preferred that R 3 is, in this embodiment, hydrogen, an alkyl group which is unsubstituted or substituted by an electron donating group, NR 4 OR 5 or ONR4R7. It is most preferred that R 3 is CH 2 -Q, wherein Q is lower alkoxy, NR 4 OR 5 or ONR 4 R 7 wherein R4 is hydrogen or alkyl containing 1-3 carbon atoms, R 5 is hydrogen or alkyl containing 1-3 carbon atoms, an R 7 is hydrogen or alkyl containing 1-3 carbon atoms.
• the preferred Ri is CH 3 .
• the most preferred R 3 is methoxy.
• the most preferred aryl is phenyl.
• the most preferred compound includes: (R)-2-acetamido-N-benzyl-3-methoxy-propionamide,
• the compounds utilized in the present invention may contain one (1) or more asymmetric carbons and may exist in racemic and optically active forms.
• the configuration around each asymmetric carbon can be either the D or L form. It is well known in the art that the configuration around a chiral carbon atoms can also be described as R or S in the Cahn- Prelog-lngold nomenclature system. All of the various configurations around each asymmetric carbon, including the various enantiomers and diastereomers as well as racemic mixtures and mixtures of enantiomers, diastereomers or both are contemplated by the present invention.
• R, R-i, R2, R3, 4. R5, Re, Z and Y are as defined previously.
• the term configuration shall refer to the configuration around the carbon atom to which R 2 and R 3 are attached, even though other chiral centers may be present in the molecule. Therefore, when referring to a particular configuration, such as D or L, it is to be understood to mean the D or L stereoisomer at the carbon atom to which R2 and R3 are attached. However, it also includes all possible enantiomers and diastereomers at other chiral centers, if any, present in the compound.
• the compounds of the present invention are directed to all the optical isomers, i.e., the compounds of the present invention are either the L-stereoisomer or the D-stereoisomer (at the carbon atom to which R2 and R 3 are attached). These stereoisomers may be found in mixtures of the L and D stereoisomer, e.g., racemic mixtures. The D stereoisomer is preferred.
• the present compounds may form addition salts as well. All of these forms are contemplated to be within the scope of this invention including mixtures of the stereoisomeric forms
• the compounds utilized in the present invention are useful as such as depicted in the Formula I or can be employed in the form of salts in view of its basic nature by the presence of the free amino group.
• the compounds of Formula I forms salts with a wide variety of acids, inorganic and organic, including pharmaceutically acceptable acids.
• the salts with therapeutically acceptable acids are of course useful in the preparation of formulation where enhanced water solubility is most advantageous. These pharmaceutically acceptable salts have also therapeutic efficacy.
• salts include salts of inorganic acids such as hydrochloric, hydroiodic, hydrobromic, phosphoric, metaphosphoric, nitric acid and sulfuric acids as well as salts of organic acids, such as tartaric, acetic, citric, malic, benzoic, perchloric, glycolic, gluconic, succinic, aryl sulfonic, (e.g., p-toluene sulfonic acids, benzenesulfonic), phosphoric, malonic, and the like.
• inorganic acids such as hydrochloric, hydroiodic, hydrobromic, phosphoric, metaphosphoric, nitric acid and sulfuric acids
• organic acids such as tartaric, acetic, citric, malic, benzoic, perchloric, glycolic, gluconic, succinic, aryl sulfonic, (e.g., p-toluene sulfonic acids, benzenes
• the compound utilized in the present invention is used in therapeutically effective amounts.
• the physician will determine the dosage of the present therapeutic agents which will be most suitable and it will vary with the form of administration and the particular compound chosen, and furthermore, it will vary with the patient under treatment, the age of the patient, the type of malady being treated. He will generally wish to initiate treatment with small dosages substantially less than the optimum dose of the compound and increase the dosage by small increments until the optimum effect under the circumstances is reached. It will generally to found that when the composition is administered orally, larger quantities of the active agent will be required to produce the same effect as a smaller quantity given parenterally.
• the compounds are useful in the same manner as comparable therapeutic agents and the dosage level is of the same order of magnitude as is generally employed with these other therapeutic agents.
• the compounds utilized are administered in amounts ranging from about 1 mg to about 100 mg per kilogram of body weight per day. This dosage regimen may be adjusted by the physician to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
• the compounds of Formula I may be administered in a convenient manner, such as by oral, intravenous (where water soluble), intramuscular or subcutaneous routes.
• the compounds of Formula (I) may be orally administered, for example, with an inert diluent or, with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets, or it may be incorporated directly into the fool of the diet.
• the active compound of Formula I may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1 % of active compound of Formula I.
• compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80 % of the weight of the unit.
• the amount of active compound of Formula I in such therapeutically useful compositions is such that a suitable dosage will beObtained.
• Preferred compositions or preparations according to the present invention contains between about 10 mg and 6 g active compound of Formula I.
• the tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring.
• a binder such as gum tragacanth, acacia, corn starch or gelatin
• excipients such as dicalcium phosphate
• a disintegrating agent such as corn starch, potato starch, alginic acid and the like
• a lubricant such as magnesium stearate
• a sweetening agent such as sucrose, lactose or saccharin may be added or a flavoring agent such as peppermint,
• any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
• the active compound may be incorporated into sustained-release preparations and formulations.
• sustained release dosage forms are contemplated wherein the active ingredient is bound to an ion exchange resin which, optionally, can be coated with a diffusion barrier coating to modify the release properties of the resin.
• the active compound may also be administered parenterally or intrapehtoneally.
• Dispersions can also be prepared in glycerol, liquid, polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
• the pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
• the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
• the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
• the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
• the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride.
• Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.
• Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
• dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
• the preferred methods of preparation are vacuum drying the freeze-drying technique plus any additional desired ingredient from previously sterile-filtered solution thereof.
• pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agent, isotonic and absorption delaying agents for pharmaceutical active substances as well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
• Dosage unit form refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
• the specifics for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material an the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such as active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired as herein disclosed in detail.
• the principal active ingredient is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in dosage unit form as hereinbefore described.
• a unit dosage form can, for example, contain the principal active compound in amounts ranging from about 10 mg to about 6 g. Expressed in proportions, the active compound is generally present in from about 1 to about 750 mg/ml of carrier. In the case of compositions containing supplementary active ingredients, the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.
• patient refers to a warm blooded animal, and preferably mammals, such as, for example, cats, dogs, horses, cows, pigs, mice, rats and primates, including humans.
• mammals such as, for example, cats, dogs, horses, cows, pigs, mice, rats and primates, including humans.
• the preferred patient is humans.
• treat refers to either relieving the pain associated with a disease or condition or alleviating the patient's disease or condition.
• the compounds of the present invention are useful for treating chronic pain.
• chronic pain is defined as pain persisting for an extended period of time, for example, greater than three to six months, although the characteristic signs described hereinbelow can occur earlier or later than this period. Vegetative signs, such as lassitude, sleep disturbances, decreased appetite, lose of taste or food, weight loss, diminished libido and constipation develop.
• Types of pain that the compounds of the present invention are especially useful in treating are is acute and chronic pain, particularly non neuropathic inflammatory pain. This include chronic inflammatory pain, e.g. rheumatoid arthritis pain and/or secondary inflammatory osteoarthritic pain.
• the compounds of the present invention are administered to a patient suffering from the aforementioned type of pain in an analgesic effective amount. These amounts are equivalent to the therapeutically effective amounts described hereinabove.
• the used substance was SPM 927 which is the synonym for Harkoseride.
• the standard chemical nomenclature is (R)-2-acetamide-N-benzyl-3-methoxypropionamide.
• Baseline data for each test was collected prior to any experimental procedure; in addition, all animals were tested for the development of chronic pain behaviours 13-25 days after CCl surgery 1 day prior to the day of vehicle (0.04 ml sterile water /10 g body weight) or drug administration and after vehicle/drug administration.
• the sequence of the tests was pain-related behaviour (1) thermal hyperalgesia, (2) mechanical allodynia in order to minimise the influence of one test on the result of the next.
• Thermal hyperalgesia was assessed by means of withdrawal latency in response to radiant heat applied to the subplantar surface of the ligated rat hind paw according to Hargreaves. As compared to the baseline latency (s), a significant decrease in the (postoperative) latency of foot withdrawal in response to the thermal stimulus was interpreted as indicating the presence of thermal hyperalgesia following chronic constriction injury.
• Acute inflammation is induced by injection of s.c. carrageenen (1.0 mg in 0.1 ml saline/paw), an unspecific inflammatory agent, into the plantar surface of one hind paw of the animal.
• Mechanical sensitivity and nociceptive thresholds were measured using an algesimeter device that exerts a constantly increasing mechanical force (10mm Hg/sec) on the inflamed hind paw.
• the mechanical nociceptive threshold is defined as the pressure (mm Hg) at which the rat vocalises or struggles or withdraws its paw. Since its original description, the Randall and Selitto mechanical paw pressure test has become a standard method for testing the efficacy of new compounds for alleviating acute inflammatory pain.
• SPM 927or vehicle sterile water, 0.04 ml/10g body weight
• SPM 927or vehicle was administered i.p réelle and 45 minutes after carrageenen, meaning 15 to 20 minutes before the start of behavioural testing.
• an increase in the pressure required to produce a behavioural response is interpreted as antinociception.
• Harkoseride proved to be anti-nociceptive in several different experimental animal models that reflect different types and symptoms of pain.
• the prolonged inflammatory nociception produced in the rat formalin test and mechanical allodynia in the rat CCl model appeared most sensitive to the effects of SPM 927, showing significant dose dependent reductions in nociceptive behaviour measurements, even at the 10 mg/kg i.p. dose.
• SPM 927 exhibited statistically significant reduction in pain on other types of nociception, thermal hyperalgesia (paw flick Hargreaves test, rat CCl model), and mechanical hyperalgesia due to acute inflammation (modified rat Randail-Selitto test).
• the anti-nociceptive profile of SPM 927 differs from classical analgesics like opioids and the standard anti-inflammatory drugs of the NSAID-type (non-steroidal anti- inflammatory drug), furthermore and surprisingly, the antinociceptive profiling obtained and described by the data given table 1 -4 is even different to other anticonvulsant drugs used for pain relief.
• SPM 927 showed dose-dependent anti-nociceptive but no anti-inflammatory effects.
• the anti-nociceptive effects started at a dose of 30mg/kg and were most prominent during the first 30min of testing.
• Morphine, as a positive control substance had clear antinociceptive effects in arthritic and normal animals.
• SPM 927 shows dose-dependent antinociceptive effects in rats that suffer from Freund's complete adjuvans induced arthritis (significant so at doses of 30 and 40mg/kg). This antinociception is not caused by potential anti-inflammatory effects. Under this chronic inflammatory pain condition the antinociceptive effect of SPM 927 (see Fig. 1) showed full intrinsic activity and suggests SPM 927 to be effective in rheumatoid arthritic pain as well as secondary inflammatory osteoarthritis.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Immunology (AREA)
• Rheumatology (AREA)
• Pain & Pain Management (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Peptides Or Proteins (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (32)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=8176844

Family Applications (1)

Country Status (30)

Cited By (13)

Families Citing this family (17)

Family Cites Families (85)

• 2001
  • 2001-03-20 AT AT01106891T patent/ATE327744T1/de not_active IP Right Cessation
  • 2001-03-20 DK DK01106891T patent/DK1243262T3/da active
  • 2001-03-20 ES ES01106891T patent/ES2262567T3/es not_active Expired - Lifetime
  • 2001-03-20 PT PT01106891T patent/PT1243262E/pt unknown
  • 2001-03-20 DE DE60120104T patent/DE60120104T2/de not_active Expired - Fee Related
  • 2001-03-20 EP EP01106891A patent/EP1243262B1/en not_active Expired - Lifetime
• 2002
  • 2002-03-19 ES ES02727437T patent/ES2326627T3/es not_active Expired - Lifetime
  • 2002-03-19 SI SI200220008A patent/SI21170A/sl not_active IP Right Cessation
  • 2002-03-19 NZ NZ523865A patent/NZ523865A/xx unknown
  • 2002-03-19 JP JP2002573793A patent/JP4955906B2/ja not_active Expired - Fee Related
  • 2002-03-19 DK DK02727437T patent/DK1373300T3/da active
  • 2002-03-19 CN CN2008101283801A patent/CN101332292B/zh not_active Expired - Fee Related
  • 2002-03-19 EA EA200300932A patent/EA007532B1/ru not_active IP Right Cessation
  • 2002-03-19 CN CNB028067614A patent/CN100415225C/zh not_active Expired - Fee Related
  • 2002-03-19 KR KR1020037002844A patent/KR100773100B1/ko not_active Expired - Fee Related
  • 2002-03-19 CZ CZ20032763A patent/CZ20032763A3/cs unknown
  • 2002-03-19 DE DE60232407T patent/DE60232407D1/de not_active Expired - Lifetime
  • 2002-03-19 SK SK1283-2003A patent/SK287539B6/sk not_active IP Right Cessation
  • 2002-03-19 UA UA2003109401A patent/UA82645C2/uk unknown
  • 2002-03-19 AU AU2002257681A patent/AU2002257681C1/en not_active Ceased
  • 2002-03-19 BR BR0205823-5A patent/BR0205823A/pt not_active Application Discontinuation
  • 2002-03-19 MX MXPA03008467A patent/MXPA03008467A/es active IP Right Grant
  • 2002-03-19 EP EP02727437A patent/EP1373300B1/en not_active Expired - Lifetime
  • 2002-03-19 PT PT02727437T patent/PT1373300E/pt unknown
  • 2002-03-19 WO PCT/EP2002/003034 patent/WO2002074784A2/en not_active Ceased
  • 2002-03-19 PL PL362985A patent/PL216213B1/pl not_active IP Right Cessation
  • 2002-03-19 HU HU0303600A patent/HUP0303600A3/hu unknown
  • 2002-03-19 AT AT02727437T patent/ATE431833T1/de active
  • 2002-03-19 DE DE122009000053C patent/DE122009000053I1/de active Pending
  • 2002-03-19 SI SI200230842T patent/SI1373300T1/sl unknown
  • 2002-03-19 IL IL15408702A patent/IL154087A0/xx unknown
  • 2002-03-19 CA CA002419397A patent/CA2419397C/en not_active Expired - Fee Related
  • 2002-03-19 US US10/344,885 patent/US6803481B2/en not_active Expired - Fee Related
• 2003
  • 2003-01-22 IL IL154087A patent/IL154087A/en not_active IP Right Cessation
  • 2003-01-31 ZA ZA200300858A patent/ZA200300858B/xx unknown
  • 2003-08-15 NO NO20033629A patent/NO20033629D0/no not_active Application Discontinuation
• 2004
  • 2004-10-08 US US10/962,240 patent/US20050085423A1/en not_active Abandoned
• 2006
  • 2006-08-21 US US11/507,110 patent/US8053476B2/en not_active Expired - Fee Related
  • 2006-08-30 CY CY20061101223T patent/CY1105533T1/el unknown
• 2009
  • 2009-08-05 LU LU91590C patent/LU91590I2/fr unknown
  • 2009-08-06 NL NL300399C patent/NL300399I1/nl unknown
  • 2009-08-12 CY CY20091100865T patent/CY1109308T1/el unknown
  • 2009-09-07 FR FR09C0041C patent/FR09C0041I2/fr active Active
  • 2009-09-16 CY CY2009013C patent/CY2009013I1/el unknown

Also Published As

Similar Documents

Legal Events